Navigation Links
VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference
Date:10/19/2007

- Company to be Featured on Oct 25, 2007 -

SAN FRANCISCO, Oct. 19 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Windhover Information has chosen the company's lead compound, VIA-2291, as one of the top ten most interesting cardiovascular projects available for partnering. VIA will be featured at Windhover Information's 2nd Annual Therapeutic Area Partnerships conference and Lawrence Cohen, Ph.D., chief executive officer and president of the company, will be providing more details about VIA-2291 at the meeting on October 25 at 2 p.m. Eastern Time in Philadelphia.

Windhover Information provides critical commentary, analysis and data to the biotech, pharmaceutical, and medical device and diagnostic industries. Its editorial and research staff, including the publishers of In Vivo and Startup, have chosen the top ten best compounds for licensing in each of four disease areas based on the following criteria: size of market, history of the molecule and drug, strength of the underlying science, diversity of potential indications, overall company strength and availability of multi-partnering opportunities.

"We are honored and delighted that VIA-2291 has been identified as one of the top cardiovascular drugs by the knowledgeable editorial and research staffs of the Windhover organization," said Dr. Cohen.

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-L
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Quintessence cancer treatment chosen for clinical studies
4. Evansville site chosen for biodiesel plant
5. Fiservs Banklink chosen by Union Bank of California
6. Detection of mRNAs on Cryosections of the Cardiovascular System Using DIG-Labeled RNA Probes
7. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
8. NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management
9. 7 Programming
10. 7 Programming
11. 7 Programming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Whether it’s used for troubleshooting in ... to a Kessler CineDrive in a cinematic studio ... the TS3-H is designed to help any shooter create ... 5MP sensor, the TS5-H offers the same convenient touchscreen controls ... , According to Tom Boldt for Fastec, “We believe ...
(Date:4/20/2015)... 2015 Stent retriever thrombectomy, an endovascular ... the brain reduced disability after stroke, according to ... President of the Society of Vascular and Interventional ... giant step forward that will change the way ... said Jovin, who is associate professor of Neurology ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 PMG ... its 12th clinical research site: PMG Research of Christie ... operation of the clinical research department at Christie ... the Southeast to a second region within the United ... physician practice enhances PMG’s access to an additional 80,000 ...
(Date:4/20/2015)... Calif. , April 20, 2015  Ardelyx, ... company focused on cardio-renal, gastrointestinal and metabolic diseases, ... MRCP, has joined the Company,s Board of Directors. ... and board level experience, having built and led ... development, regulatory approval and into healthcare systems globally. ...
Breaking Biology Technology:Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4
... DNA-Based Test Produces Decisive Result Within Minutes, ... Enigma Diagnostics,the life sciences company developing rapid ... has successfully completed a project,commissioned by the ... a rapid, point-of-care diagnostic system for screening ...
... Nov. 8 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... 30, 2007. Net loss for the quarter and nine ... or $0.26 per share and $0.46 per share,compared to a ... and,$0.76 per share, in the same periods last year. ...
... The Organizations Advocating Use of Hand ... Prevention and Protection, NORCROSS, Ga., Nov. 8 ... and the media continue,to report daily on recent school ... to this drug-resistant staph infection*. Even though,hand-washing is advocated ...
Cached Biology Technology:Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 2Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme 3Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7Soap and Water May not be Enough to Fight MRSA Superbug 2Soap and Water May not be Enough to Fight MRSA Superbug 3
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... There,s a wobbly new biochemical structure in Burckhard Seelig,s ... what enzymes looked like billions of years ago, when ... they became ingredients for new and improved products, from ... fledgling enzyme by using directed evolution in the laboratory. ...
... , JUPITER, FL, January 30, 2013 It takes a ... synthesized, neuron structures altered. While some of these memory-building mechanisms ... that a unique group of molecules called microRNAs, known to ... more important role in memory formation than previously thought. ...
... School Team 1 won the Colorado High School Science Bowl ... Bowl in Washington D.C., Apr. 25-29, where they will compete ... 70 high schools. The U.S. Department of Energy (DOE) ... to encourage high school students to explore math and science. ...
Cached Biology News:U. of Minn. researchers unveil first artificial enzyme created by evolution in a test tube 2Scientists uncover previously unknown mechanism of memory formation 2
Cells are grown in triple flasks, roller bottles, or NUNC Factory. Viability and growth curves are generated from a parallel representative culture....
... against a large variety of antigens. ... provided with personalized project proposals and ... by Covance remain exclusive property of ... project has four phases: immunization, fusion, ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... T7Select Packaging Extracts are optimized for maximum ... insert. The high efficiency extracts (> 109 ... to produce a library containing at least ... arms. The extracts are made from a ...
Biology Products: